Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Male or female ≥ 18 years of age~* Histologically proven metastatic colorectal cancer~* Molecular testing showing RAS wild-type in colorectal carcinoma cells~* Life expectancy \> 12 weeks~* At least one measurable lesion according to RECIST 1.1~* Adequate bone marrow, liver, kidney, organ and metabolic function~* Bone marrow function:~  * leukocyte count ≥ 3.0 × 109/L~ * ANC ≥ 1.5 × 109/L~ * platelet count ≥ 100 × 109/L~ * hemoglobin ≥ 9 g/dL or 5.59 mmol/L (may be transfused or treated with erythropoietin to maintain/ exceed this level)~* Hepatic function:~  * Total bilirubin ≤ 1.5 × UNL~ * ALT and AST ≤ 2.5 × UNL (or ≤ 5 × UNL in presence of liver metastases)~ * AP ≤ 5 × UNL~* Renal function:~  * Creatinine clearance ≥ 50 mL/min according to Cockcroft-Gault formula or serum creatinine ≤ 1.5 × UNL~* Metabolic function:~  * Magnesium ≥ lower limit of normal~ * Calcium ≥ lower limit of normal~* ECOG performance status 0 - 1~* Women of child-bearing potential must have a negative pregnancy test~Exclusion Criteria:~* Previous treatment for colorectal cancer in the metastatic setting~* Previous EGFR-targeting therapy \< 6 months after end of adjuvant therapy~* Known brain metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids~* Chronic inflammatory bowel disease~* Peripheral neuropathy ≥ NCI-CTCAE V 4.03 grade 2~* Other previous malignancies with the exception of a history of previous curatively treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix or other curatively treated malignant disease without recurrence after at least 5 years of follow-up~* Significant disease that, in the investigator's opinion, would exclude the patient from the study~* History of cardiac disease; defined as:~  * Congestive heart failure \> New York Heart Association (NYHA) class 2~ * Active coronary artery disease (myocardial infarction more than 6 months prior to start of study treatment is allowed)~ * Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted)~ * Uncontrolled hypertension (defined as blood pressure ≥ 160 mmHg systolic and/or ≥ 90 mmHg diastolic on medication)~* Patients with interstitial lung disease, e.g., pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan~* Known HIV, hepatitis B or C infection~* Known hypersensitivity reaction to any of the study components~* Radiotherapy, major surgery or any investigational drug 30 days before registration~* Pregnancy or lactation or planning to be pregnant during treatment and within 6 months after the end of treatment~* Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for at least an additional 6 months after the end of treatment~* Known alcohol or drug abuse~* Any condition that is unstable or could jeopardize the safety of the patient and his compliance in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Maintenance Chemotherapy + Panitumumab (Type: EXPERIMENTAL): Maintenance therapy:~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15
- Maintenance Chemotherapy w/o Panitumumab (Type: EXPERIMENTAL): Maintenance therapy:~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete